New Rules of the Road in TTP Management
In July 2020, the International Society on Thrombosis and Haemostasis (ISTH) issued its first-ever guidelines for the treatment of thrombotic thrombocytopenic purpura (TTP), helping...
The Year in FDA Approvals
Here, we review recent therapies approved by the U.S. Food and Drug Administration for the treatment of red blood cell and iron disorders, including...
Investigating Tyrosine Kinase Inhibitors for ITP
In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators shared updates on two kinase inhibitors for the treatment...
Tranexamic Acid for Gastrointestinal Bleeding: Time to HALT-IT?
Although tranexamic acid reduces the risks of surgical bleeding and bleeding-related death in patients with trauma, it does not reduce risk of death from...
ADAMTS13 Activity Levels Predict iTTP Recurrence
A study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress confirms the value of longitudinal quarterly assessment of ADAMTS13...
Studies Confirm Long-Term Benefit of Gene Therapy for Hemophilia A
In two studies presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress, gene therapies for hemophilia A demonstrated durable increases...
Small Retrospective Study Suggests Thrombopoietin Receptor Agonists Are Safe, Likely Effective for ITP During...
Preliminary findings from an observational multicenter study suggest that temporary off-label use of thrombopoietin receptor agonists (TPO-RAs) for the treatment of severe and/or refractory...
Extended Half-Life Factor VIII Fusion Protein Effective in Previously Untreated Hemophilia A
The use of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) appeared to be safe and effective in young boys with previously untreated...
FLT180a: A New Gene Therapy Candidate for Severe Hemophilia B
In a small study of patients with severe hemophilia B, the novel adeno-associated virus (AAV) gene therapy FLT180a was associated with increased factor IX...
Caplacizumab Produces Faster, Sustained Platelet Count Responses Than Placebo in aTTP
Patients with acquired thrombotic thrombocytopenic purpura (aTTP) who were treated with caplacizumab – anti–von Willebrand factor humanized immunoglobulin – experienced a faster and more...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.